+

WO2008063769A3 - Altérations de l'expression du gène erg spécifiques au cancer de la prostate, et procédés de détection et de traitement en fonction de ces altérations - Google Patents

Altérations de l'expression du gène erg spécifiques au cancer de la prostate, et procédés de détection et de traitement en fonction de ces altérations Download PDF

Info

Publication number
WO2008063769A3
WO2008063769A3 PCT/US2007/080826 US2007080826W WO2008063769A3 WO 2008063769 A3 WO2008063769 A3 WO 2008063769A3 US 2007080826 W US2007080826 W US 2007080826W WO 2008063769 A3 WO2008063769 A3 WO 2008063769A3
Authority
WO
WIPO (PCT)
Prior art keywords
alterations
prostate cancer
gene expression
detection
erg
Prior art date
Application number
PCT/US2007/080826
Other languages
English (en)
Other versions
WO2008063769A2 (fr
WO2008063769A9 (fr
Inventor
Shiv Srivastava
Albert Dobi
Taduru Sreenath
Gyorgy Petrovics
Chen Sun
Original Assignee
Shiv Srivastava
Albert Dobi
Taduru Sreenath
Gyorgy Petrovics
Chen Sun
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shiv Srivastava, Albert Dobi, Taduru Sreenath, Gyorgy Petrovics, Chen Sun filed Critical Shiv Srivastava
Priority to CA2664630A priority Critical patent/CA2664630C/fr
Priority to EP07868397.6A priority patent/EP2074225B1/fr
Priority to US12/444,903 priority patent/US8541169B2/en
Priority to JP2009532537A priority patent/JP5470041B2/ja
Priority to AU2007324128A priority patent/AU2007324128B2/en
Priority to US12/081,101 priority patent/US9206481B2/en
Publication of WO2008063769A2 publication Critical patent/WO2008063769A2/fr
Publication of WO2008063769A9 publication Critical patent/WO2008063769A9/fr
Publication of WO2008063769A3 publication Critical patent/WO2008063769A3/fr
Priority to US13/974,007 priority patent/US10287587B2/en
Priority to US14/928,917 priority patent/US20160115481A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention décrit des altérations de l'expression du gène ERG. Sont fournies des isoformes d'ERG et une séquence de promoteurs du gène ERG impliqués dans le cancer de la prostate ou associés à celui-ci. L'invention fournit en outre des compositions thérapeutiques et des procédés pour détecter, diagnostiquer, pronostiquer et traiter un cancer de la prostate, y compris des biomarqueurs pour détecter l'expression de deux des gènes suivants ou plus : PSA/KLK3, PMEPM, NKX3.1, ODC1, AMD1, et ERG.
PCT/US2007/080826 2006-10-10 2007-10-09 Altérations de l'expression du gène erg spécifiques au cancer de la prostate, et procédés de détection et de traitement en fonction de ces altérations WO2008063769A2 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
CA2664630A CA2664630C (fr) 2006-10-10 2007-10-09 Alterations de l'expression du gene erg specifiques au cancer de la prostate, et procedes de detection et de traitement en fonction de ces alterations
EP07868397.6A EP2074225B1 (fr) 2006-10-10 2007-10-09 Altérations de l'expression du gène erg spécifiques au cancer de la prostate, et procédés de détection et de traitement en fonction de ces altérations
US12/444,903 US8541169B2 (en) 2006-10-10 2007-10-09 Prostate cancer-specific alternations in ERG gene expression and detection and treatment methods based on those alterations
JP2009532537A JP5470041B2 (ja) 2006-10-10 2007-10-09 Ｅｒｇ遺伝子発現における前立腺癌特異的変化ならびにそれらの変化に基づく検出および治療方法
AU2007324128A AU2007324128B2 (en) 2006-10-10 2007-10-09 Prostate cancer-specific alterations in ERG gene expression and detection and treatment methods based on those alterations
US12/081,101 US9206481B2 (en) 2006-10-10 2008-04-10 Prostate cancer-specific alterations in ERG gene expression and detection and treatment methods based on those alterations
US13/974,007 US10287587B2 (en) 2006-10-10 2013-08-22 Prostate cancer-specific alterations in ERG gene expression and detection and treatment methods based on those alterations
US14/928,917 US20160115481A1 (en) 2006-10-10 2015-10-30 Prostate cancer-specific alterations in erg gene expression and detection and treatment methods based on those alterations

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US85025406P 2006-10-10 2006-10-10
US60/850,254 2006-10-10
US92950507P 2007-06-29 2007-06-29
US60/929,505 2007-06-29

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US12/444,903 A-371-Of-International US8541169B2 (en) 2006-10-10 2007-10-09 Prostate cancer-specific alternations in ERG gene expression and detection and treatment methods based on those alterations
US12/081,101 Continuation-In-Part US9206481B2 (en) 2006-10-10 2008-04-10 Prostate cancer-specific alterations in ERG gene expression and detection and treatment methods based on those alterations
US13/974,007 Continuation US10287587B2 (en) 2006-10-10 2013-08-22 Prostate cancer-specific alterations in ERG gene expression and detection and treatment methods based on those alterations

Publications (3)

Publication Number Publication Date
WO2008063769A2 WO2008063769A2 (fr) 2008-05-29
WO2008063769A9 WO2008063769A9 (fr) 2008-07-10
WO2008063769A3 true WO2008063769A3 (fr) 2008-12-18

Family

ID=39430412

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/080826 WO2008063769A2 (fr) 2006-10-10 2007-10-09 Altérations de l'expression du gène erg spécifiques au cancer de la prostate, et procédés de détection et de traitement en fonction de ces altérations

Country Status (6)

Country Link
US (4) US8541169B2 (fr)
EP (3) EP2518163B1 (fr)
JP (3) JP5470041B2 (fr)
AU (1) AU2007324128B2 (fr)
CA (2) CA2664630C (fr)
WO (1) WO2008063769A2 (fr)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8043835B1 (en) 1996-03-26 2011-10-25 Oncomedx, Inc. Methods for detecting and monitoring cancer using extracellular RNA
CA2250118C (fr) * 1996-03-26 2009-09-29 Michael S. Kopreski Procede permettant d'employer de l'arn extracellulaire extrait de plasma ou de serum a la detection, a la surveillance ou a l'evaluation d'un cancer
US20080261292A1 (en) * 1998-09-22 2008-10-23 Oncomedx, Inc. Method Enabling the Use of Extracellular Ribonucleic Acid (RNA) Extracted from Plasma or Serum to Detect, Monitor or Evaluate Cancer or Premalignant Conditions
US20100159464A1 (en) * 2001-11-05 2010-06-24 Oncomedx, Inc. Method for Detection of DNA Methyltransferase RNA in Plasma and Serum
GB0307428D0 (en) 2003-03-31 2003-05-07 Medical Res Council Compartmentalised combinatorial chemistry
US20060078893A1 (en) 2004-10-12 2006-04-13 Medical Research Council Compartmentalised combinatorial chemistry by microfluidic control
GB0307403D0 (en) 2003-03-31 2003-05-07 Medical Res Council Selection by compartmentalised screening
US20050221339A1 (en) 2004-03-31 2005-10-06 Medical Research Council Harvard University Compartmentalised screening by microfluidic control
US7968287B2 (en) 2004-10-08 2011-06-28 Medical Research Council Harvard University In vitro evolution in microfluidic systems
US11105808B2 (en) 2004-11-12 2021-08-31 Health Discovery Corporation Methods for screening, predicting and monitoring prostate cancer
US7718369B2 (en) 2005-09-12 2010-05-18 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
US9957569B2 (en) * 2005-09-12 2018-05-01 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
US20100137163A1 (en) 2006-01-11 2010-06-03 Link Darren R Microfluidic Devices and Methods of Use in The Formation and Control of Nanoreactors
WO2008063227A2 (fr) 2006-05-11 2008-05-29 Raindance Technologies, Inc. Dispositifs microfluidiques
US9562837B2 (en) 2006-05-11 2017-02-07 Raindance Technologies, Inc. Systems for handling microfludic droplets
WO2008021123A1 (fr) 2006-08-07 2008-02-21 President And Fellows Of Harvard College Tensioactifs fluorocarbonés stabilisateurs d'émulsions
EP2518163B1 (fr) 2006-10-10 2014-08-06 The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. Modifications spécifiques du cancer de la prostate dans l'expression du gène ERG et procédés de détection sur la base de ces altérations
WO2008058239A2 (fr) * 2006-11-08 2008-05-15 The Regents Of The University Of Michigan Spink1 en tant que marqueur du cancer de la prostate et ses utilisations
WO2008097559A2 (fr) 2007-02-06 2008-08-14 Brandeis University Manipulation de fluides et de réactions dans des systèmes microfluidiques
WO2008130623A1 (fr) 2007-04-19 2008-10-30 Brandeis University Manipulation de fluides, composants fluidiques et réactions dans des systèmes microfluidiques
AU2008275303B2 (en) 2007-07-06 2012-05-03 The Regents Of The University Of Michigan MIPOL1-ETV1 gene rearrangements
US20090136942A1 (en) * 2007-09-18 2009-05-28 Oncomedx, Inc. Analysis of Extracellular RNA
US8191002B2 (en) 2007-10-15 2012-05-29 International Business Machines Corporation Summarizing portlet usage in a portal page
AU2008354371B2 (en) * 2008-04-10 2015-07-09 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Prostate cancer-specific alterations in ERG gene expression and detection and treatment methods based on those alterations
WO2009143603A1 (fr) 2008-05-28 2009-12-03 Genomedx Biosciences, Inc. Systèmes et procédés de discrimination basée sur l’expression d’états pathologiques cliniques distincts dans le cancer de la prostate
US12038438B2 (en) 2008-07-18 2024-07-16 Bio-Rad Laboratories, Inc. Enzyme quantification
WO2010009365A1 (fr) 2008-07-18 2010-01-21 Raindance Technologies, Inc. Bibliothèque de gouttelettes
US8528589B2 (en) 2009-03-23 2013-09-10 Raindance Technologies, Inc. Manipulation of microfluidic droplets
JP5918694B2 (ja) 2009-05-12 2016-05-18 コーニンクレッカ フィリップス エヌ ヴェＫｏｎｉｎｋｌｉｊｋｅ Ｐｈｉｌｉｐｓ Ｎ．Ｖ． 前立腺がんのマーカーとしてのホスホジエステラーゼ９ａ
KR101778036B1 (ko) 2009-05-12 2017-09-14 코닌클리케 필립스 엔.브이. 전립선암 마커로서의 포스포디에스테라제 4ｄ7
US8426133B2 (en) * 2009-05-26 2013-04-23 Quest Diagnostics Investments Incorporated Methods for detecting gene dysregulation by intragenic differential expression
AU2010295689B2 (en) * 2009-09-17 2014-02-13 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
WO2011042564A1 (fr) 2009-10-09 2011-04-14 Universite De Strasbourg Nanomatériau marqué à base de silice à propriétés améliorées et ses utilisations
US8546552B2 (en) 2009-12-23 2013-10-01 Quest Diagnostics Investments Incorporated TMPRSS2 for the diagnosis of prostate disease
EP2517025B1 (fr) 2009-12-23 2019-11-27 Bio-Rad Laboratories, Inc. Procédés pour réduire l'échange de molécules entre des gouttelettes
US9399797B2 (en) 2010-02-12 2016-07-26 Raindance Technologies, Inc. Digital analyte analysis
US10351905B2 (en) 2010-02-12 2019-07-16 Bio-Rad Laboratories, Inc. Digital analyte analysis
EP3392349A1 (fr) 2010-02-12 2018-10-24 Raindance Technologies, Inc. Analyse numérique d'analytes
US9366632B2 (en) 2010-02-12 2016-06-14 Raindance Technologies, Inc. Digital analyte analysis
WO2012024640A2 (fr) * 2010-08-20 2012-02-23 Cedars-Sinai Medical Center Mst1 comme biomarqueur de pronostic et cible thérapeutique dans un cancer humain
WO2012045012A2 (fr) 2010-09-30 2012-04-05 Raindance Technologies, Inc. Dosages sandwich dans des gouttelettes
US8945556B2 (en) 2010-11-19 2015-02-03 The Regents Of The University Of Michigan RAF gene fusions
US20130267443A1 (en) 2010-11-19 2013-10-10 The Regents Of The University Of Michigan ncRNA AND USES THEREOF
US9364803B2 (en) 2011-02-11 2016-06-14 Raindance Technologies, Inc. Methods for forming mixed droplets
EP3736281A1 (fr) 2011-02-18 2020-11-11 Bio-Rad Laboratories, Inc. Compositions et méthodes de marquage moléculaire
WO2012167142A2 (fr) 2011-06-02 2012-12-06 Raindance Technolgies, Inc. Quantification d'enzyme
US8841071B2 (en) 2011-06-02 2014-09-23 Raindance Technologies, Inc. Sample multiplexing
US8658430B2 (en) 2011-07-20 2014-02-25 Raindance Technologies, Inc. Manipulating droplet size
CA2858383A1 (fr) * 2011-12-09 2013-06-13 British Columbia Cancer Agency Branch Prediction de pronostic dans un lymphome de hodgkin classique
WO2013120089A1 (fr) 2012-02-10 2013-08-15 Raindance Technologies, Inc. Dosage de type criblage diagnostique moléculaire
WO2013165748A1 (fr) 2012-04-30 2013-11-07 Raindance Technologies, Inc Analyse d'analyte numérique
AU2013302365B2 (en) 2012-08-16 2019-03-21 Mayo Foundation For Medical Education And Research Cancer diagnostics using biomarkers
JP6044935B2 (ja) 2013-03-11 2016-12-14 学校法人日本大学 新規ｐｉポリアミド
EP2986762B1 (fr) 2013-04-19 2019-11-06 Bio-Rad Laboratories, Inc. Analyse d'analyte numérique
US20160213754A1 (en) * 2013-09-20 2016-07-28 Nils LANDEGREN Transglutaminase 4 as a prostate specific autoantigen and the methods of use thereof
US11901041B2 (en) 2013-10-04 2024-02-13 Bio-Rad Laboratories, Inc. Digital analysis of nucleic acid modification
US9944977B2 (en) 2013-12-12 2018-04-17 Raindance Technologies, Inc. Distinguishing rare variations in a nucleic acid sequence from a sample
WO2015103367A1 (fr) 2013-12-31 2015-07-09 Raindance Technologies, Inc. Système et procédé de détection d'une espèce d'arn
JP6630285B2 (ja) * 2014-03-12 2020-01-15 ザ ヘンリー エム． ジャクソン ファウンデーション フォー ザ アドヴァンスメント オブ ミリタリー メディシン インコーポレイテッド Ｅｒｇ発癌遺伝子陽性癌のための新規阻害剤
US10647981B1 (en) 2015-09-08 2020-05-12 Bio-Rad Laboratories, Inc. Nucleic acid library generation methods and compositions
US20190204322A1 (en) * 2015-09-09 2019-07-04 Genomedx Biosciences, Inc. Molecular subtyping, prognosis and treatment of prostate cancer
JP6920683B2 (ja) 2015-10-08 2021-08-18 凸版印刷株式会社 ピロールイミダゾール含有ポリアミドを用いた標的二本鎖核酸分子の濃縮方法およびキット
CN110506127B (zh) 2016-08-24 2024-01-12 维拉科特Sd公司 基因组标签预测前列腺癌患者对术后放射疗法应答性的用途
CA3050984A1 (fr) 2017-01-20 2018-07-26 Decipher Biosciences, Inc. Sous-typage moleculaire, pronostic et traitement du cancer de la vessie
US11873532B2 (en) 2017-03-09 2024-01-16 Decipher Biosciences, Inc. Subtyping prostate cancer to predict response to hormone therapy
US11078542B2 (en) 2017-05-12 2021-08-03 Decipher Biosciences, Inc. Genetic signatures to predict prostate cancer metastasis and identify tumor aggressiveness
US10998178B2 (en) 2017-08-28 2021-05-04 Purdue Research Foundation Systems and methods for sample analysis using swabs

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005113816A2 (fr) * 2004-05-07 2005-12-01 Henry M. Jackson Foundation For The Advancement Of Military Medicine Methodes de diagnostic ou de traitement du cancer de la prostate au moyen du gene erg, seul ou combine a d'autres genes surexprimes ou sous-exprimes dans le cancer de la prostate

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5283174A (en) 1987-09-21 1994-02-01 Gen-Probe, Incorporated Homogenous protection assay
EP0710719B1 (fr) 1990-01-12 2007-03-14 Amgen Fremont Inc. Génération d'anticorps xénogeniques
EP0553235A1 (fr) 1990-10-01 1993-08-04 The University Of Connecticut Ciblage de virus et de cellules pour leur inclusion selective dans des cellules
JPH06510524A (ja) 1991-05-14 1994-11-24 ユニバーシティ オブ コネチカット 免疫原性タンパク質をコードする遺伝子の標的への配達
DE69231385T2 (de) 1991-06-05 2001-04-12 The Board Of Regents Acting For And On Behalf Of The Unversity Of Michigan, Ann Arbor Zielgerichtete freisetzung von genen, die sekretorische proteine kodieren
WO1993014188A1 (fr) 1992-01-17 1993-07-22 The Regents Of The University Of Michigan Virus cible
JPH07505773A (ja) 1992-04-03 1995-06-29 ヤング　アレキサンダー　ティー 標的化されたウイルスベクターを用いた遺伝子治療
US5830645A (en) * 1994-12-09 1998-11-03 The Regents Of The University Of California Comparative fluorescence hybridization to nucleic acid arrays
US8048629B2 (en) 1996-03-15 2011-11-01 The Penn State Research Foundation Detection of extracellular tumor-associated nucleic acid in blood plasma or serum
US6054316A (en) 1999-06-25 2000-04-25 Isis Pharmaceuticals Inc. Antisense inhibition of ETs-2 expression
WO2001029262A2 (fr) 1999-10-15 2001-04-26 Orchid Biosciences, Inc. Reactifs de genotypage, kits et procedes d'utilisation desdits reactifs
EP1290217A2 (fr) * 2000-02-04 2003-03-12 Aeomica, Inc. Procedes et appareil destines a predire, a confirmer, et a afficher des informations fonctionnelles derivees d'une sequence genomique
US8202979B2 (en) 2002-02-20 2012-06-19 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
US20030165843A1 (en) 2000-07-28 2003-09-04 Avi Shoshan Oligonucleotide library for detecting RNA transcripts and splice variants that populate a transcriptome
DE10057755A1 (de) * 2000-11-22 2002-05-23 Bayer Ag Phosphomevalonat Kinasen aus Pflanzen
US7892730B2 (en) * 2000-12-22 2011-02-22 Sagres Discovery, Inc. Compositions and methods for cancer
US20030148519A1 (en) 2001-11-14 2003-08-07 Engelke David R. Intracellular expression and delivery of siRNAs in mammalian cells
AU2003214363A1 (en) * 2002-02-13 2003-09-04 Axordia Limited Method to modify differentiation of pluripotential stem cells
DK1487972T3 (en) * 2002-02-21 2015-10-19 Inst Virology MN / CA IX-specific monoclonal antibodies generated from MN / CA IX-poor mice, as well as methods of use.
US20040241707A1 (en) * 2002-04-01 2004-12-02 Gao Chun L. Enhanced diagnostic potential of prostate-specific antigen expressing cells
US7217807B2 (en) 2002-11-26 2007-05-15 Rosetta Genomics Ltd Bioinformatically detectable group of novel HIV regulatory genes and uses thereof
US20040181821A1 (en) 2003-03-14 2004-09-16 Jiadong Zhou siRNA research tool kit
US20070048738A1 (en) 2003-07-14 2007-03-01 Mayo Foundation For Medical Education And Research Methods and compositions for diagnosis, staging and prognosis of prostate cancer
EP1737956A2 (fr) 2004-03-01 2007-01-03 Massachusetts Institute of Technology Agents therapeutiques a base d'arni pour le traitement de la rhinite allergique et de l'asthme
US7374927B2 (en) * 2004-05-03 2008-05-20 Affymetrix, Inc. Methods of analysis of degraded nucleic acid samples
AU2005243410B2 (en) 2004-05-14 2010-04-22 Rosetta Genomics Ltd. Micronas and uses thereof
US7718369B2 (en) 2005-09-12 2010-05-18 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
EP2518163B1 (fr) * 2006-10-10 2014-08-06 The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. Modifications spécifiques du cancer de la prostate dans l'expression du gène ERG et procédés de détection sur la base de ces altérations

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005113816A2 (fr) * 2004-05-07 2005-12-01 Henry M. Jackson Foundation For The Advancement Of Military Medicine Methodes de diagnostic ou de traitement du cancer de la prostate au moyen du gene erg, seul ou combine a d'autres genes surexprimes ou sous-exprimes dans le cancer de la prostate

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE GENBANK [online] NCBI; 23 December 2003 (2003-12-23), OWCZAREK CM ET AL: "Detailed mapping of the ERG-ETS2 interval of human chromosome 21 and comparison with the region of conserved synteny on mouse chromosome 16.", XP002487173, retrieved from GENBANK Database accession no. AY204742 *
OWCZAREK C M ET AL: "Detailed mapping of the ERG-ETS2 interval of human chromosome 21 and comparison with the region of conserved synteny on mouse chromosome 16", GENE, ELSEVIER, AMSTERDAM, NL, vol. 324, 7 January 2004 (2004-01-07), pages 65 - 77, XP004482475, ISSN: 0378-1119 *
PETROVICS GYORGY ET AL: "Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome", ONCOGENE, BASINGSTOKE, HANTS, GB, vol. 24, no. 23, 26 May 2005 (2005-05-26), pages 3847 - 3852, XP002464141, ISSN: 0950-9232 *
TOMLINS SCOTT A ET AL: "Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer", SCIENCE, WASHINGTON, DC, vol. 310, no. 5748, 28 October 2005 (2005-10-28), pages 644 - 648, XP002464140, ISSN: 0036-8075 *

Also Published As

Publication number Publication date
AU2007324128B2 (en) 2013-10-10
CA2664630A1 (fr) 2008-05-29
EP2837697A3 (fr) 2015-02-25
CA2664630C (fr) 2018-11-27
WO2008063769A2 (fr) 2008-05-29
US20160115481A1 (en) 2016-04-28
JP6078484B2 (ja) 2017-02-08
US9206481B2 (en) 2015-12-08
EP2518163A3 (fr) 2013-02-06
US8541169B2 (en) 2013-09-24
EP2837697B1 (fr) 2016-12-07
JP5470041B2 (ja) 2014-04-16
AU2007324128A1 (en) 2008-05-29
US20100144832A1 (en) 2010-06-10
CA3018520A1 (fr) 2008-05-29
US10287587B2 (en) 2019-05-14
US20080269157A1 (en) 2008-10-30
WO2008063769A9 (fr) 2008-07-10
JP2010505446A (ja) 2010-02-25
EP2518163B1 (fr) 2014-08-06
JP2014113162A (ja) 2014-06-26
JP2016165270A (ja) 2016-09-15
JP6383743B2 (ja) 2018-08-29
US20150044670A1 (en) 2015-02-12
EP2837697A2 (fr) 2015-02-18
EP2518163A2 (fr) 2012-10-31
EP2074225A2 (fr) 2009-07-01
EP2074225B1 (fr) 2014-12-03
CA3018520C (fr) 2022-05-17

Similar Documents

Publication Publication Date Title
WO2008063769A3 (fr) Altérations de l'expression du gène erg spécifiques au cancer de la prostate, et procédés de détection et de traitement en fonction de ces altérations
MX2010000405A (es) Seleccion de farmacos para terapia de cancer de pulmon usando arreglos a base de anticuerpos.
WO2005113816A3 (fr) Methodes de diagnostic ou de traitement du cancer de la prostate au moyen du gene erg, seul ou combine a d'autres genes surexprimes ou sous-exprimes dans le cancer de la prostate
WO2006110264A3 (fr) Procedes et compositions permettant de predire le deces du au cancer et la survie au cancer de la prostate a l'aide de signatures d'expression genique
WO2007112330A8 (fr) Compositions et méthodes pour détecter, pronostiquer et traiter un cancer du côlon
EP2527466A3 (fr) Variants génétiques du CHR2 utilisés comme marqueurs dans l'évaluation, le diagnostic, le pronostic et le traitement d'un risque de cancer du sein
WO2007093657A3 (fr) Procédé destiné au diagnostic moléculaire du cancer de la prostate et nécessaire destiné à mettre en oeuvre ce procédé
IL207637A (en) Choosing a Breast Cancer Remedy Using Antibody-Based Arrays
WO2007081680A3 (fr) Anomalies dans l'expression des micro-arn dans des tumeurs endocrines pancréatiques et des tumeurs à cellules acineuses
WO2010099161A8 (fr) Microarn chez les non-fumeurs et méthodes et matières apparentées
MX2009012625A (es) Metodos para el tratamiento, diagnostico y deteccion de trastornos asociados con el fgf21.
WO2007084992A3 (fr) Marqueurs prédictifs utilisés à des fins de pronostic et de traitement et leurs méthodes d'utilisation
WO2008073899A3 (fr) Compositions associées à prrg4 et procédés d'utilisation de celles-ci dans des procédés de diagnostic de tumeur
WO2009026128A3 (fr) Marqueurs d'expression de gène de risque de récurrence chez des patients atteints de cancer après une chimiothérapie
WO2008097466A3 (fr) Variantes d'épissages spécifiques métastatiques de mena, et utilisation de celles-ci dans le diagnostic, le pronostic et le traitement de tumeurs
WO2007140352A3 (fr) Membrane plasmatique et biomarqueurs de cancer sécrétés
EP4435112A3 (fr) Compositions et procédés de criblage de tumeurs solides
MX2013000502A (es) Metodos y kits para el diagnostico de cancer de prostata.
MX2009005058A (es) Metodos para tratar, diagnosticar o detectar cancer.
WO2005116259A3 (fr) Utilisation du profilage de l'expression genetique pour prevoir les chances de survie d'un patient atteint d'un cancer
WO2008115750A3 (fr) Compositions et procédés pour le traitement du cancer
WO2008008923A3 (fr) Compositions et procédés pour cibler des complexes de transcription spécifiques du cancer
Huang et al. Anti-apoptotic signature in thymic squamous cell carcinomas–functional relevance of anti-apoptotic BIRC3 expression in the thymic carcinoma cell line 1889c
WO2008070472A3 (fr) Utilisation de plasma hsp90 lié à une malignité
WO2007033167A3 (fr) Compositions et methodes de detection et de traitement du cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07868397

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2664630

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2007868397

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2009532537

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 12444903

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007324128

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2007324128

Country of ref document: AU

Date of ref document: 20071009

Kind code of ref document: A

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载